{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:25:23Z","timestamp":1791581123675,"version":"4.3.4"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the short-term effectiveness of guselkumab in patients with psoriatic arthritis (PsA) and suggestive features of axial involvement in a prospective \u2018real-life\u2019 multicentre cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Between June 2022 and June 2023, PsA patients with axial involvement were evaluated if treated at least for 4\u2009months with guselkumab. The effectiveness was evaluated by BASDAI, ASDAS, DAPSA, and achievement of BASDAI \u2264 4, also exploiting predictive factors. In a group of patients, MRI findings on sacroiliac joints were assessed before and after guselkumab administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixty-seven patients with PsA and suggestive features of axial involvement (age 53.4\u2009\u00b1\u200911.2\u2009years, male sex 26.9%) were treated with guselkumab. After 4\u2009months, a significant reduction of BASDAI, ASDAS, and DAPSA was observed. A \u0394BASDAI of \u22122.11\u2009\u00b1\u20090.43 was estimated assessing the mean difference values before and after guselkumab administration and 52.2% of patients reached a BASDAI \u2264 4. In 27 patients, MRI findings on sacroiliac joints were assessed before and after guselkumab administration. A reduction of 0.80 or larger in the sacroiliac joint lesion score was observed in the majority of patients (70.3%) based on MRI improvements, paralleling with the clinical response. No life-threatening side effects were recorded; 17.9% of patients reported minor adverse events mainly injection site reactions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The short-term effectiveness of guselkumab in patients with PsA and suggestive features of axial involvement were shown. Although further studies are needed, our multicentre \u2018real-life\u2019 study may suggest the clinical usability of guselkumab in this context.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae220","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T18:13:05Z","timestamp":1712772785000},"page":"1122-1130","source":"Crossref","is-referenced-by-count":13,"title":["Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort"],"prefix":"10.1093","volume":"64","author":[{"given":"Piero","family":"Ruscitti","sequence":"first","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila , L'Aquila,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Pantano","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, School of Medicine and Surgery, University della Campania \u201cLuigi Vanvitelli\u201d , Naples,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Cataldi","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila , L'Aquila,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Gentile","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila , L'Aquila,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Arrigoni","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila , L'Aquila,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Riccio","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, School of Medicine and Surgery, University della Campania \u201cLuigi Vanvitelli\u201d , Naples,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Marrone","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, School of Medicine and Surgery, University della Campania \u201cLuigi Vanvitelli\u201d , Naples,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Mauro","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, School of Medicine and Surgery, University della Campania \u201cLuigi Vanvitelli\u201d , Naples,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-8642","authenticated-orcid":false,"given":"Francesco","family":"Ursini","sequence":"additional","affiliation":[{"name":"Medicine & Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli , Bologna,","place":["Italy"]},{"name":"Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum University of Bologna , Bologna,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila , L'Aquila,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Barile","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila , L'Aquila,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila , L'Aquila,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome \u201cCampus Bio-Medico\u201d , Rome,","place":["Italy"]},{"name":"Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Universitario Campus Bio-Medico , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9352-1264","authenticated-orcid":false,"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, School of Medicine and Surgery, University della Campania \u201cLuigi Vanvitelli\u201d , Naples,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cipriani","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila , L'Aquila,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"2025030500185152200_keae220-B1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025030500185152200_keae220-B2","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.semarthrit.2021.06.006","article-title":"Axial involvement in psoriatic arthritis: an update for rheumatologists","volume":"51","author":"Poddubnyy","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2025030500185152200_keae220-B3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","article-title":"Psoriatic arthritis from a mechanistic perspective","volume":"18","author":"Schett","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025030500185152200_keae220-B4","doi-asserted-by":"crossref","first-page":"1229516","DOI":"10.3389\/fimmu.2023.1229516","article-title":"Cytokine profile characterization of na\u00efve patients with psoriasis and psoriatic arthritis: implications for a pathogenic disease continuum","volume":"14","author":"Ruscitti","year":"2023","journal-title":"Front Immunol"},{"key":"2025030500185152200_keae220-B5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025030500185152200_keae220-B6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025030500185152200_keae220-B7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12026-023-09366-4","article-title":"Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials","volume":"71","author":"Huang","year":"2023","journal-title":"Immunol Res"},{"key":"2025030500185152200_keae220-B8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"2025030500185152200_keae220-B9","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"2025030500185152200_keae220-B10","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","article-title":"Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies","volume":"3","author":"Mease","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025030500185152200_keae220-B11","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"key":"2025030500185152200_keae220-B12","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/rheumatology\/keab509","article-title":"Real-life efficacy of guselkumab in patients with early psoriatic arthritis","volume":"61","author":"Pantano","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500185152200_keae220-B13","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/annrheumdis-2021-221422","article-title":"No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related \u2018physician-reported spondylitis\u2019?","volume":"81","author":"Braun","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025030500185152200_keae220-B14","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2025030500185152200_keae220-B15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11926-007-0074-2","article-title":"Axial disease in psoriatic arthritis","volume":"9","author":"Gladman","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"2025030500185152200_keae220-B16","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.21445","article-title":"Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis","volume":"53","author":"Maksymowych","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025030500185152200_keae220-B17","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s40744-023-00592-8","article-title":"Efficacy of guselkumab on axial-related symptoms through up to 2 years in adults with active psoriatic arthritis in the phase 3, randomized, placebo-controlled DISCOVER-2 study","volume":"10","author":"Mease","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025030500185152200_keae220-B18","doi-asserted-by":"crossref","first-page":"818413","DOI":"10.3389\/fimmu.2022.818413","article-title":"No significant effects of IL-23 on initiating and perpetuating the axial spondyloarthritis: the reasons for the failure of IL-23 inhibitors","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"2025030500185152200_keae220-B19","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/rheumatology\/kez457","article-title":"Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?","volume":"59","author":"Feld","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500185152200_keae220-B20","doi-asserted-by":"crossref","first-page":"e002956","DOI":"10.1136\/rmdopen-2022-002956","article-title":"Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry","volume":"9","author":"Ciurea","year":"2023","journal-title":"RMD Open"},{"key":"2025030500185152200_keae220-B21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)","volume":"81","author":"Coates","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025030500185152200_keae220-B22","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.2147\/DMSO.S405374","article-title":"Insulin stimulates IL-23 expression in human adipocytes: a possible explanation for the higher prevalence of psoriasis in obesity","volume":"16","author":"Di Vincenzo","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2025030500185152200_keae220-B23","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/jdv.16273","article-title":"The role of the interleukin-23\/Th17 pathway in cardiometabolic comorbidity associated with psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025030500185152200_keae220-B24","doi-asserted-by":"crossref","first-page":"103357","DOI":"10.1016\/j.autrev.2023.103357","article-title":"Effect of body mass index on treatment response of biologic\/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review","volume":"22","author":"Gialouri","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2025030500185152200_keae220-B25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13075-023-03105-8","article-title":"Serum IL-23 significantly decreased in obese patients with psoriatic arthritis six months after a structured weight loss intervention","volume":"25","author":"Landgren","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"2025030500185152200_keae220-B26","first-page":"30","article-title":"Updates on axial psoriatic arthritis from the 2020 GRAPPA annual meeting","volume":"97","author":"Gladman","year":"2021","journal-title":"J Rheumatol Suppl"},{"key":"2025030500185152200_keae220-B27","doi-asserted-by":"crossref","first-page":"1759720X211057975","DOI":"10.1177\/1759720X211057975","article-title":"Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)","volume":"13","author":"Poddubnyy","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025030500185152200_keae220-B28","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1016\/S2665-9913(21)00141-7","article-title":"How should we define disease and outcomes in axial psoriatic arthritis?","volume":"3","author":"Coates","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025030500185152200_keae220-B29","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/art.38050","article-title":"Magnetic resonance imaging assessment of axial psoriatic arthritis: extent of disease relates to HLA-B27","volume":"65","author":"Castillo-Gallego","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025030500185152200_keae220-B30","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41584-023-01038-9","article-title":"Predominant ligament-centric soft-tissue involvement differentiates axial psoriatic arthritis from ankylosing spondylitis","volume":"19","author":"McGonagle","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2025030500185152200_keae220-B31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41584-023-00986-6","article-title":"The bone marrow side of axial spondyloarthritis","volume":"19","author":"Mauro","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2025030500185152200_keae220-B32","doi-asserted-by":"crossref","first-page":"e002011","DOI":"10.1136\/rmdopen-2021-002011","article-title":"Characterising axial psoriatic arthritis: correlation between whole spine MRI abnormalities and clinical, laboratory and radiographic findings","volume":"8","author":"Diaz","year":"2022","journal-title":"RMD Open"},{"key":"2025030500185152200_keae220-B33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/rheumatology\/kead162","article-title":"Magnetic resonance imaging characteristics in patients with psoriatic arthritis and axial manifestations from the MAXIMISE cohort","volume":"63","author":"Baraliakos","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500185152200_keae220-B34","doi-asserted-by":"crossref","first-page":"102738","DOI":"10.1016\/j.autrev.2020.102738","article-title":"The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus","volume":"20","author":"Giacomelli","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2025030500185152200_keae220-B35","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.autrev.2017.07.012","article-title":"International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: the unmet needs and the clinical grey zone in autoimmune disease management","volume":"16","author":"Giacomelli","year":"2017","journal-title":"Autoimmun Rev"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae220\/57362152\/keae220.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1122\/57362152\/keae220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1122\/57362152\/keae220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:22:15Z","timestamp":1741134135000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/3\/1122\/7643731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,4,10]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae220","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,4,10]]}}}